

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

CLARIFICATION ANNOUNCEMENT RELATING TO THE 2020 RESULTS ANNOUNCEMENT

References are made to the annual results announcement of RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司 (the “**Company**”) for the year ended December 31, 2020 dated March 26, 2021 (the “**2020 Results Announcement**”). Unless otherwise indicated, capitalised terms used herein shall have the same meanings as those defined in the 2020 Results Announcement.

The Company confirmed that under International Accounting Standard 33, the new shares issued through the initial public offering on November 9, 2020 and the exercise of the over-allotment option on December 7, 2020 should be included in the weighted average number of shares from the date consideration is receivable (i.e. the date of their issue). Therefore, the weighted average number of ordinary shares of the Company (the “**Shares**”) for the year ended December 31, 2020 and December 31, 2019 for the purposes of calculating the basic and diluted loss per share in the 2020 Results Announcement should have been 408,148,548 Shares and 260,470,517 Shares instead of 482,141,630 Shares and 347,521,728, respectively.

Accordingly, the Company clarified and confirmed that the basic and diluted loss per share of the Company for the year ended December 31, 2020 in the 2020 Results Announcement should have been RMB1.71 instead of RMB1.45 and the basic and diluted loss per share of the Company for the year ended December 31, 2019 should have been RMB1.65 instead of RMB1.24.

Save as disclosed above, all other information as stated in the 2020 Results Announcement remain unchanged.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
April 23, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Lorne Alan Babiuk as the independent non-executive directors.

* For identification purposes only